Lower-dose chemo plus blinatumomab before stem cell transplant for ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of a lower-dose chemotherapy and a short course of an immunotherapy drug called blinatumomab, before a stem cell transplant, to see if it helps improve outcomes for adults with certain types of ALL.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a newly diagnosed type of acute lymphoblastic leukemia (ALL) that is CD19-positive and does not have the Philadelphia chromosome.
- You are planning to have a stem cell transplant and have a suitable donor (matched sibling, matched unrelated, or half-matched).
- Your vital organs such as heart, liver, kidneys, and lungs are working well enough (specific tests will check this).
- You agree to use effective contraception during treatment and for at least 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
Hear when a new Acute Lymphoid Leukemia (ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.